摘要
目的观察艾塞那肽对不同体质量指数(BMI)的2型糖尿病患者的疗效及安全性。方法 62例经口服降糖药物治疗而血糖控制不佳(HbA1c≥7.0%)的2型糖尿病患者,依据BMI分为3组,A组(正常组,19≤BMI<24),B组(超重组,24≤BMI<28),C组(肥胖组,BMI≥28)。3组均加用艾塞那肽。12周后比较3组治疗前、后糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2hPG)、血脂、体质量、收缩压(SBP)、舒张压(DBP)的变化,记录低血糖发生的次数及不良反应。结果 3组患者HbA1c、FPG、2hPG、血甘油三酯(TG)与治疗前相比均有明显降低(P<0.01),血高密度脂蛋白胆固醇(HDL-C)较治疗前明显升高(P<0.05),B组及C组体质量、BMI与治疗前相比也有明显下降(分别为P<0.05,P<0.01),同时两组SBP、DBP也有显著降低(P<0.05)。结论艾塞那肽更适用于超重及肥胖的2型糖尿病患者。
Objective To research the efficacy and safty of exenatide in type 2 diabetes patients with different body mass index（BMI）. Methods Totally 62 patients with type 2 diabetes treated with oral antidiabetic drugs and with inade- quately glucose controlled were enrolled. These patients were selected and randomized into 3 groups by BMI, group A（ 19 BMI 〈 24）, group B （24 ≤ BMI 〈 28 ）, group C （ BMI ≥28 ）. All patients received exenatide for 12 weeks without chan- ging their basal therapy. Before treatment and after glycated hemoglobin A1 c （HbAlc）, fasting plasma glucose （FPG）, postprandial 2 h plasma （ 2 hPG ）, total cholesterol （ TC ） , triglycolides （ TG ） , weight, systolic blood pressure （ SBP）, diatolic blood pressure （DBP） were measured and compared. Results In 3 groups HbA1 c, FPG,2hPG, TG were all significantly decreased（P 〈0. 05）,HDL- C were significantly increased（P 〈0. 05）. In group B and C weight,BMI were reduced significantly（ P 〈 0. 05,P 〈 0. 01 ）, and SBP, DBP were decreased （ P 〈 0. 05 ）. Conclusion The therapy with exenatide is more suitable for overweight and obese tyoe 2 diabetic patiens.
出处
《医药论坛杂志》
2014年第2期44-46,共3页
Journal of Medical Forum
